Biosimilars closed to commercialization challenges against a multinational company
Domestic biosimilar development companies, highly anticipated to acquire approvals soon, are underway to nullify patents and launch their products early.
In order to launch their products early, Samsung Bioepis and Celltrion have challenged to patents of Humira(adalimumab, Abbott) and Mabthera(...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
